Russell Pachynski, MD

Medical Oncologist

Russell Pachynski

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

Expertise & Training

Video thumbnail for Russell Pachynski, MD

Watch video on YouTube

Russell Pachynski, MD

3 mins

Washington University medical oncologist Russell Pachynski, MD, discusses what patients with genitourinary cancers can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Pachynski: https://siteman.wustl.edu/doctor/pachynski-russell-md/

Learn more about the Siteman Approach to Prostate Cancer: https://siteman.wustl.edu/treatment/cancer-types/prostate/our-approach/

Prostate cancer patients have more treatment options than ever before. Learn about how improved treatments are leading to better outcomes: https://siteman.wustl.edu/prostate-cancer-treatment-options/

Clinical Expertise

Primary Academic Title

Associate Professor of Medicine, Division of Medical Oncology, Director of GU Oncology Research, WashU Medicine

Board Certification

  • 2007: American Board of Internal Medicine
  • 2017: American Board of Internal Medicine, Medical Oncology

Training

  • 2003 - 2006: Resident, Internal Medicine, Stanford University Medical Center, Stanford, CA
  • 2006 - 2010: Fellow, Oncology, Stanford University Medical Centner, Stanford, CA

Education

  • 2003: MD, University of Wisconsin-Madison Medical School, Madison, WI

Research & Selected Publications

Research Programs

My clinical specialty is genitourinary cancers, with a focus on prostate cancer. I also maintain an active lab focusing on leukocyte trafficking and its role in tumor immunology, with the ultimate goal of advantageously controlling this for patients’ benefits. I hope to advance translational immunotherapy and be able to bring novel therapies from the bench to the bedside, and back again.

Research Publications

Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic
Authors:

Somani VK, Zhang X, Chen TH, one or more additional authors omitted Pachynski RK, one or more additional authors omitted Lim KH

Journal & Year:

Mol Cancer | 2026

Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer
Authors:

Rawat K, Punia V, Mathews P, one or more additional authors omitted Pachynski RK

Journal & Year:

J Immunother Cancer | 2025

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations
Authors:

Einstein DJ, Abel ML, Aragon-Ching JB, one or more additional authors omitted Pachynski RK, one or more additional authors omitted Madan RA

Journal & Year:

J Clin Oncol | 2025

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Mali…
Authors:

Luke JJ, Gelmon K, Siu LL, one or more additional authors omitted Pachynski RK, one or more additional authors omitted Tabernero J

Journal & Year:

Clin Cancer Res | 2025

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
Authors:

Petrylak DP, Ratta R, Matsubara N, one or more additional authors omitted Pachynski R, one or more additional authors omitted Fizazi K

Journal & Year:

J Clin Oncol | 2025

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer
Authors:

Sweis RF, Chatta GS, Jain RK, one or more additional authors omitted Pachynski RK, Yu EY

Journal & Year:

Clin Cancer Res | 2025

Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Authors:

Chauhan PS, Alahi I, Sinha S, one or more additional authors omitted Pachynski RK, one or more additional authors omitted Chaudhuri AA

Journal & Year:

Clin Cancer Res | 2025

Tumour evolution and microenvironment interactions in 2D and 3D space
Authors:

Mo CK, Liu J, Chen S, one or more additional authors omitted Pachynski R, one or more additional authors omitted Ding L

Journal & Year:

Nature | 2024